206 related articles for article (PubMed ID: 37470597)
1. Endometrial cancer risk factors, treatment, and survival outcomes as per the European Society for Medical Oncology (ESMO) - European Society of Gynaecological Oncology (ESGO) - European Society for Radiotherapy and Oncology (ESTRO) risk groups and International Federation of Gynecology and Obstetrics (FIGO) staging: An experience from developing world.
Gupta N; Pandey A; Dimri K; Sehgal A; Bhagat R; Suraj ; Gill G
J Cancer Res Ther; 2023; 19(3):701-707. PubMed ID: 37470597
[TBL] [Abstract][Full Text] [Related]
2. Multi-institutional validation of the ESMO-ESGO-ESTRO consensus conference risk grouping in Turkish endometrial cancer patients treated with comprehensive surgical staging.
Gultekin M; Guler OC; Yuce Sari S; Akkus Yildirim B; Onal C; Celik H; Yuce K; Ayhan A; Arik Z; Kose F; Altundag O; Zoto Mustafayev T; Atalar B; Bolukbasi Y; Yildiz F
J Obstet Gynaecol; 2021 Apr; 41(3):414-420. PubMed ID: 32347768
[TBL] [Abstract][Full Text] [Related]
3. Call for Surgical Nodal Staging in Women with ESMO/ESGO/ESTRO High-Intermediate Risk Endometrial Cancer: A Multicentre Cohort Analysis from the FRANCOGYN Study Group.
Ouldamer L; Bendifallah S; Body G; Canlorbe G; Touboul C; Graesslin O; Raimond E; Collinet P; Coutant C; Lavoué V; Lévêque J; Daraï E; Ballester M;
Ann Surg Oncol; 2017 Jun; 24(6):1660-1666. PubMed ID: 28058558
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Recurrence, Long-term Survival and Toxicity Analysis of Endometrial Adenocarcinoma Patients Reclassified Under the Recent ESMO-ESGO-ESTRO Stratification: Seven-Year Results From a Single Institution.
Kumar UP; Yathiraj PH; Sharan KT; Kamath A; Singh A; Reddy SA; Alurkar P; Fernandes DJ; Mamidipudi VS
Int J Gynecol Cancer; 2018 Jun; 28(5):854-860. PubMed ID: 29683879
[TBL] [Abstract][Full Text] [Related]
5. Preoperative MR imaging for ESMO-ESGO-ESTRO classification of endometrial cancer.
Lavaud P; Fedida B; Canlorbe G; Bendifallah S; Darai E; Thomassin-Naggara I
Diagn Interv Imaging; 2018 Jun; 99(6):387-396. PubMed ID: 29472031
[TBL] [Abstract][Full Text] [Related]
6. Concordance between preoperative ESMO-ESGO-ESTRO risk classification and final histology in early-stage endometrial cancer.
Daix M; Angeles MA; Migliorelli F; Kakkos A; Martinez Gomez C; Delbecque K; Mery E; Tock S; Gabiache E; Decuypere M; Goffin F; Martinez A; Ferron G; Kridelka F
J Gynecol Oncol; 2021 Jul; 32(4):e48. PubMed ID: 33908709
[TBL] [Abstract][Full Text] [Related]
7. Identification of
Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
[TBL] [Abstract][Full Text] [Related]
8. Abnormal preoperative haematological parameters in Endometrial cancer; reflecting tumour aggressiveness or reduced response to radiotherapy?
Vrede SW; Donkers H; Reijnen C; Smits A; Visser NCM; Geomini PM; Ngo H; van Hamont D; Pijlman BM; Vos MC; Snijders MPLM; Kruitwagen R; Bekkers RLM; Galaal K; Pijnenborg JMA
J Obstet Gynaecol; 2024 Dec; 44(1):2294332. PubMed ID: 38186008
[TBL] [Abstract][Full Text] [Related]
9. Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score-matched analysis.
Nero C; Pasciuto T; Cappuccio S; Corrado G; Pelligra S; Zannoni GF; Santoro A; Piermattei A; Minucci A; Lorusso D; Fanfani F; Scambia G
Cancer; 2022 Aug; 128(15):2898-2907. PubMed ID: 35617463
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
Vrede SW; van Weelden WJ; Visser NCM; Bulten J; van der Putten LJM; van de Vijver K; Santacana M; Colas E; Gil-Moreno A; Moiola CP; Mancebo G; Krakstad C; Trovik J; Haldorsen IS; Huvila J; Koskas M; Weinberger V; Bednarikova M; Hausnerova J; van der Wurff AA; Matias-Guiu X; Amant F; ; Snijders MPLM; Küsters-Vandevelde HVN; Reijnen C; Pijnenborg JMA
Gynecol Oncol; 2021 Jun; 161(3):787-794. PubMed ID: 33858677
[TBL] [Abstract][Full Text] [Related]
11. Machine learning endometrial cancer risk prediction model: integrating guidelines of European Society for Medical Oncology with the tumor immune framework.
Bruno V; Betti M; D'Ambrosio L; Massacci A; Chiofalo B; Pietropolli A; Piaggio G; Ciliberto G; Nisticò P; Pallocca M; Buda A; Vizza E
Int J Gynecol Cancer; 2023 Nov; 33(11):1708-1714. PubMed ID: 37875322
[TBL] [Abstract][Full Text] [Related]
12. Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients - An international pooled analysis of three ESGO accredited centres.
Schwameis R; Fanfani F; Ebner C; Zimmermann N; Peters I; Nero C; Marth C; Ristl R; Leitner K; Grimm C; Oberndorfer F; Capasso I; Zeimet AG; Polterauer S; Scambia G; Fagotti A; Concin N
Eur J Cancer; 2023 Nov; 193():113317. PubMed ID: 37748967
[TBL] [Abstract][Full Text] [Related]
13. FIGO 2023 endometrial cancer staging: too much, too soon?
McCluggage WG; Bosse T; Gilks CB; Howitt BE; McAlpine JN; Nucci MR; Rabban JT; Singh N; Talia KL; Parra-Herran C
Int J Gynecol Cancer; 2023 Nov; ():. PubMed ID: 37935523
[TBL] [Abstract][Full Text] [Related]
14. Recurrent patterns after postoperative radiotherapy for early stage endometrial cancer: A competing risk analysis model.
Ren K; Wang W; Sun S; Hou X; Hu K; Zhang F
Cancer Med; 2022 Jan; 11(1):257-267. PubMed ID: 34779587
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes of Uterine Body Cancers Treated in a Tertiary Cancer Center.
Muthulingeshkumar K; Pandjatcharam J; Chaturvedula L
South Asian J Cancer; 2023 Jan; 12(1):87-92. PubMed ID: 36860588
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy for advanced endometrial cancer.
Galaal K; Al Moundhri M; Bryant A; Lopes AD; Lawrie TA
Cochrane Database Syst Rev; 2014 May; 2014(5):CD010681. PubMed ID: 24832785
[TBL] [Abstract][Full Text] [Related]
17. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer.
Cibula D; Pötter R; Planchamp F; Avall-Lundqvist E; Fischerova D; Haie Meder C; Köhler C; Landoni F; Lax S; Lindegaard JC; Mahantshetty U; Mathevet P; McCluggage WG; McCormack M; Naik R; Nout R; Pignata S; Ponce J; Querleu D; Raspagliesi F; Rodolakis A; Tamussino K; Wimberger P; Raspollini MR
Radiother Oncol; 2018 Jun; 127(3):404-416. PubMed ID: 29728273
[TBL] [Abstract][Full Text] [Related]
18. Analysis of postoperative radiotherapy effects within risk groups in patients with FIGO I, II, and III endometrial cancer.
Popovic V; Milosavljevic N; Radojevic MZ; Vojinovic RH; Nedovic N; Mitrovic S; Nedovic J; Tomasevic A
Indian J Cancer; 2019; 56(4):341-347. PubMed ID: 31607704
[TBL] [Abstract][Full Text] [Related]
19. The impact of the type of nodal assessment on prognosis in patients with high-intermediate and high-risk ESMO/ESGO/ESTRO group endometrial cancer. A multicenter Italian study.
Buda A; Restaino S; Di Martino G; De Ponti E; Monterossi G; Dinoi G; Magni S; Quagliozzi L; Dell'Orto F; Ciccarone F; Lamanna M; Scambia G; Landoni F; Fanfani F
Eur J Surg Oncol; 2018 Oct; 44(10):1562-1567. PubMed ID: 30077521
[TBL] [Abstract][Full Text] [Related]
20. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
